What is Holmusk?
Founded in 2015 and headquartered in Singapore, Holmusk operates at the intersection of advanced data science and clinical healthcare. The company has developed a robust RWE platform specifically designed to address the complexities of neuroscience and chronic disease management. By synthesizing scientific research with digital healthcare data, Holmusk provides actionable intelligence that enables stakeholders—including biopharma companies, health plans, and clinical providers—to improve patient outcomes and operational efficiency. The company's proprietary modeling platform is engineered to transform raw clinical data into predictive insights, effectively bridging the gap between traditional medical research and modern, personalized treatment protocols.
How much funding has Holmusk raised?
Holmusk has raised a total of $76.3M across 3 funding rounds:
Angel/Seed
$9.8M
Series A
$21.5M
Series B
$45M
Angel/Seed (2018): $9.8M with participation from Heritas Capital and Capikris Foundation
Series A (2020): $21.5M led by Optum Ventures, Heritas Capital, and Health Catalyst Capital Management
Series B (2023): $45M supported by Heritas Capital, Northwell Health, Veradigm, Health Catalyst Capital Management, and Novartis
Key Investors in Holmusk
Heritas Capital
Heritas Venture Fund is a Singapore-based investment firm managing private equity and venture capital funds with a dedicated focus on the healthcare, education, and technology sectors.
Health Catalyst Capital Management
A New York-based private equity firm specializing in high-growth healthcare information technology and tech-enabled services, aiming to improve care quality and affordability.
Optum Ventures
The venture capital arm of Optum, focused on investing in early-stage companies that are poised to disrupt the status quo and improve the healthcare system for all stakeholders.
What's next for Holmusk?
With the successful closure of this major enterprise-level funding round, Holmusk is well-positioned to accelerate its product development roadmap and expand its footprint in the global healthcare ecosystem. The strategic capital will likely be deployed to enhance the scalability of its RWE platform and deepen its integration with existing clinical workflows. As the demand for data-driven healthcare solutions continues to rise, Holmusk's focus on actionable, evidence-based insights will be instrumental in driving the next generation of personalized medicine. Future growth initiatives are expected to center on strengthening partnerships with large-scale healthcare providers and pharmaceutical innovators to further validate its predictive models across diverse therapeutic areas.
See full Holmusk company page
